Kinase Inhibitor News and Research

RSS
A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
Study identifies potential Achilles heel of kinase-driven cancers

Study identifies potential Achilles heel of kinase-driven cancers

Penn studies provide new understanding of lung cancer progression and prevention

Penn studies provide new understanding of lung cancer progression and prevention

Drug could activate innate anti-tumor immunity to eradicate aggressive prostate cancer in mice

Drug could activate innate anti-tumor immunity to eradicate aggressive prostate cancer in mice

Study provides insight into how microRNA may amplify effects of drug treatment in liver cancer

Study provides insight into how microRNA may amplify effects of drug treatment in liver cancer

Researchers uncover mechanism of resistance used by triple negative breast cancer

Researchers uncover mechanism of resistance used by triple negative breast cancer

Researchers discover Hedgehog signaling pathway is key to formation of gastrointestinal stromal tumors

Researchers discover Hedgehog signaling pathway is key to formation of gastrointestinal stromal tumors

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

New drug holds potential for treating advanced mastocytosis

New drug holds potential for treating advanced mastocytosis

Researchers discover novel neuroprotection strategies to slow progression of Parkinson's disease

Researchers discover novel neuroprotection strategies to slow progression of Parkinson's disease

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

Leukemia drug increases brain dopamine, lowers toxic proteins linked to Parkinson's or dementia

ALK fusion variants could influence NSCLC crizotinib response

ALK fusion variants could influence NSCLC crizotinib response

Cabozantinib extends advanced RCC overall survival

Cabozantinib extends advanced RCC overall survival

Salvage alloSCT remains option for progressing CML patients

Salvage alloSCT remains option for progressing CML patients

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Long-term dasatinib findings support first-line use in CML

Long-term dasatinib findings support first-line use in CML

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

CML treatment-free remission criteria outlined

CML treatment-free remission criteria outlined